X

Clinical Trials

Contact Us

Lung Cancer

AFT-31 (NCT02967133)

Nivolumab with or without nab-paclitaxel in previously treated, advanced stage, non small cell lung cancer: A randomized phase II study


A221504 (NCT03087708)

A Randomized, Double-Blind, Placebo-Controlled Pilot of Naloxegol (an Oral, Selective Peripheral Opioid Receptor Antagonist) in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)


NRG LU002 (NCT03137771)

Maintenance systemic therapy versus consolidative sterotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer: A randomized phases II/III trial.


NRG CC003 (NCT02635009) – Temporarily Closed

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer


Alliance C30610 (NCT00632835)

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide


S1507 (NCT02642042)

A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies


NRG-CC001 (NCT02360215)

A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases


SWOG S1400 (NCT02154490)

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)


SWOG S1403 (NCT02438722)

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)


AFT09 (NCT02591615)

Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer